Jonathan Lim

Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer

Andrea Sartore‐Bianchi, Elena Ardini, Roberta Bosotti et al. · JNCI Journal of the National Cancer Institute · 2015 · 245 citations · Full text

Medicine, Molecular Medicine, Oncology +17

STARTRK-1: Phase 1/2a study of entrectinib, an oral Pan-Trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations.

Manish R. Patel, Todd M. Bauer, Stephen V. Liu et al. · Journal of Clinical Oncology · 2015 · 48 citations

Medicine, Oncology, Pharmacology +13

Health Care Resource Utilization, Costs, and Persistence in Patients Newly Diagnosed as Having Nonvalvular Atrial Fibrillation and Newly Treated With Dabigatran versus Warfarin in the United States

Tim Bancroft, Jonathan Lim, Cheng Wang et al. · Clinical Therapeutics · 2016 · 32 citations · Full text

Medicine, Cardiology, Pharmacoeconomics +13

Impact of Evidence‐Based Stroke Care on Patient Outcomes: A Multilevel Analysis of an International Study

Paula Muñoz Venturelli, Xian Li, Sandy Middleton et al. · Journal of the American Heart Association · 2019 · 27 citations · Full text

Medicine, Rehabilitation Medicine, Evidence-based Practice +16

Treatment patterns, resource use and costs of idiopathic pulmonary fibrosis in Spain – results of a Delphi Panel

Ferrán Morell, Jonathan Lim, Susanne Stowasser et al. · BMC Pulmonary Medicine · 2016 · 26 citations · Full text

Pharmacy, Internal Medicine, Pharmacoeconomics +17